胸腺肽α1辅助治疗结核性胸膜炎的疗效观察  

The effect of the thymosin α1 in adjuvant treatment of the tuberculous pleurisy

作　　者：焦昕[1] 刘宁[1] JIAO Xin;LIU Ning(Department of Respiratory,Shenyang Chest Hospital,Shenyang ,Liaoning110031,China)

机构地区：[1]沈阳市胸科医院呼吸科

出　　处：《热带医学杂志》2018年第11期1455-1457,1518,共4页Journal of Tropical Medicine

基　　金：辽宁省自然科学基金计划(20170540995)

摘　　要：目的研究胸腺肽α1辅助治疗结核性胸膜炎的效果,探讨糖类抗原125(CA125)和D-二聚体的变化对疗效的预测价值。方法收集2010年4月至2017年2月于本院诊治的结核性胸膜炎患者108例为试验对象,随机分为实验组和对照组,对照组给予常规治疗(胸腔穿刺抽液和2HRZE/10HRE方案抗结核治疗),实验组给予胸腺肽α1皮下注射联合常规治疗。比较两组患者临床症状缓解速度及缓解率、影像学吸收时间、胸水CA125和血D-二聚体的变化情况。结果与对照组相比,联合应用胸腺肽α1后,患者的临床症状缓解速度更快,缓解率更高,影像学吸收明显加快,胸水中CA125及血D-二聚体的下降速度也明显加快,差异均有统计学意义(P<0.05)。结论辅助应用胸腺肽α1可明显提高结核性胸膜炎的疗效,缩短住院时间,动态监测胸水CA125和血D-二聚体的变化可能有助于预测患者的病情转归。Objective To investigate the clinical efficacy of thymosin α1 in adjuvant treatment of the tuberculous pleurisy,and explore the predictive effect of CA125 and D-dimer on the adjuvant treatment results of thymosin α1. Methods A total of 108 cases of patients with tuberculous pleurisy treated in our hospital from April 2010 to February 2017 were selected and randomly divided into study group and control group. Patients in the control group were treated with routine treatment(thoracentesis and 2 HRZE/10 HRE chemotherapy),and the study group was treated with thymosin α1 and routine treatment. The clinical curative effect reaction of the two groups were observed. The expression of CA125 and D-dimer was assessed. Results After thymosin α1 was added to the routine treatment,the patient′s symptom was relieved significantly faster than that of the control group. The rate of symptoms remission was significantly higher than that of the control group.The imaging absorption was significantly accelerated. The downregulations of CA125 and D-dimer were also accelerated. The differences between the two groups were statistically significant(P<0.05). Conclusion Thymosin α1 could profoundly improve the clinical therapeutic outcomes of tuberculous pleurisy. Dynamic monitoring the changes of blood D-dimer and pleural-fluid CA125 could predict the clinical efficacy of thymosin α1.

关 键 词：CA125 D-二聚体 胸腺肽Α1 结核性胸膜炎 

分 类 号：R521.7[医药卫生—内科学]